Pharmaceuticals: USD3.7bn in 2014 to USD3.9bn in 2015; +5.6%. Our forecast has been revised upwards since Q115 due to historical data.

Healthcare: USD16.8bn in 2014 to USD17.8bn in 2015; +5.7 %. Our forecast has been revised upwards since Q115 due to revised historical data.

Risk/Reward Index

Based on our analysis and assessment of the market's appeal to pharmaceutical companies in our Q215 Pharmaceutical Risk/Reward Index (RRIs), the Americas scores 50.9 out of 100, below Western Europe (67.4), Asia Pacific (52.9), and Central and Eastern Europe (51.1), but above the Middle East and Africa (42.5). Of the seven Central American countries surveyed Panama's RRI score ranks first at 44.0, followed by Costa Rica (43.2), Guatemala (38.8), Belize (37.8), Honduras (37.0), Nicaragua (35.5) and El Salvador (35.0).

Key Trends And Developments

In January 2015, delegates from Panama's Ministry of Health travelled to Costa Rica in order to seek advice on Panama's plans to create a unified health system. The two countries plan to work together in order to strengthen Panamanian healthcare in coming years.

In December 2014, the Honduran Ministry of Health signed an agreement with the National Anti-Corruption Council (CNA) under which the Ministry will facilitate the surveillance of the delivery and distribution of medicines and other medical supplies throughout the country. This agreement will also help to fight the recent rise in general nationwide corruption.

In December 2014, Costa Rica created the National Commission on Health Research (CONIS). CONIS is recognised through Article 34 of Law 9234, which was...

Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

Benefit from discounts when you add multiple products to your basket

2 Products

SAVE 10%

3 Products

SAVE 15%

4 Products

SAVE 20%

5 Products

SAVE 25%

6 Products

SAVE 30%

7 - 20 Products

SAVE 35%

21 Products or more

SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’